{"transactions":[{"id":767591,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T20:30:16.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":24122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":66718,"source":{"system":"sec-edgar","filing":"0001193125-26-234572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000119312526234572/ownership.xml","form_type":"4"}},{"id":1030612,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":37276,"kind":"person","name":"Heron Patrick J","position":1,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":5,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-30T20:59:56.000Z","date":"2025-09-26","kind":"purchase","planned":false,"acquired":true,"shares":666666,"price":18,"value":11999988.0,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5219440,"source":{"system":"sec-edgar","filing":"0001231919-25-000267","document":"form4-09302025_080948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000123191925000267/form4-09302025_080948.xml","form_type":"4"}},{"id":1038108,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-17T21:22:34.000Z","date":"2025-09-15","kind":"purchase","planned":false,"acquired":true,"shares":660,"price":23.6953,"value":15638.898,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.46 to $23.75. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3028524,"source":{"system":"sec-edgar","filing":"0001341382-25-000007","document":"form4-09172025_090930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000134138225000007/form4-09172025_090930.xml","form_type":"4"}},{"id":1037367,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T21:20:18.000Z","date":"2025-09-17","kind":"other","planned":false,"acquired":false,"shares":17199,"price":1.95,"value":33538.05,"ownership":{"direct":false,"nature":"By Patrick J. Heron"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit (\"RSU\") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001790879-25-000007","document":"form4-09172025_090911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000179087925000007/form4-09172025_090911.xml","form_type":"4"}},{"id":1037366,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T21:20:18.000Z","date":"2025-09-17","kind":"other","planned":false,"acquired":false,"shares":8535337,"price":1.95,"value":16643907.15,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation (\"Parent\") and XRA 4 Corp., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each share of the Issuer's Common Stock, par value $0.0001 per share (\"Shares\"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001790879-25-000007","document":"form4-09172025_090911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000179087925000007/form4-09172025_090911.xml","form_type":"4"}},{"id":1044129,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-10T21:19:10.000Z","date":"2025-09-08","kind":"purchase","planned":false,"acquired":true,"shares":1260,"price":24.99,"value":31487.4,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.86 to $25.00. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3027864,"source":{"system":"sec-edgar","filing":"0001415889-25-024111","document":"form4-09102025_090907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925024111/form4-09102025_090907.xml","form_type":"4"}},{"id":1067955,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-13T20:49:54.000Z","date":"2025-08-11","kind":"purchase","planned":false,"acquired":true,"shares":471,"price":23.9787,"value":11293.9677,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.91 to $24.00. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3026604,"source":{"system":"sec-edgar","filing":"0001415889-25-021660","document":"form4-08132025_080851.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925021660/form4-08132025_080851.xml","form_type":"4"}},{"id":1101169,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-06-26T23:41:52.000Z","date":"2025-06-25","kind":"purchase","planned":false,"acquired":true,"shares":1260,"price":18.2632,"value":23011.632,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.10 to $18.3795. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3026133,"source":{"system":"sec-edgar","filing":"0001415889-25-018316","document":"form4-06262025_110648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925018316/form4-06262025_110648.xml","form_type":"4"}},{"id":1101168,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-06-26T23:41:52.000Z","date":"2025-06-24","kind":"purchase","planned":false,"acquired":true,"shares":2520,"price":18.4343,"value":46454.436,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.305 to $18.63. inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of shares beneficially owned includes an additional incremental purchase of 200 shares on March 26, 2025, which was inadvertently omitted from the Form 4 filed on March 28, 2025"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3024873,"source":{"system":"sec-edgar","filing":"0001415889-25-018316","document":"form4-06262025_110648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925018316/form4-06262025_110648.xml","form_type":"4"}},{"id":1106555,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-06-18T20:42:40.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":8584,"price":19.4992,"value":167381.1328,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.20 to $19.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3022153,"source":{"system":"sec-edgar","filing":"0001415889-25-017693","document":"form4-06182025_080636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925017693/form4-06182025_080636.xml","form_type":"4"}},{"id":1121001,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:56:34.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the firstanniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vestingdate."}],"balance_after":17500,"derivative":{"exercise_price":4.95,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-082454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000095017025082454/ownership.xml","form_type":"4"}},{"id":1121000,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:56:34.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":42596,"source":{"system":"sec-edgar","filing":"0000950170-25-082454","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000095017025082454/ownership.xml","form_type":"4"}},{"id":1134909,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T20:06:35.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":3780,"price":3.8649,"value":14609.322,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":59403,"source":{"system":"sec-edgar","filing":"0001415889-25-014428","document":"form4-05232025_080527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925014428/form4-05232025_080527.xml","form_type":"4"}},{"id":1147096,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:17:38.000Z","date":"2025-05-14","kind":"purchase","planned":false,"acquired":true,"shares":6300,"price":3.3205,"value":20919.15,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.215 to $3.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":55623,"source":{"system":"sec-edgar","filing":"0001415889-25-013134","document":"form4-05152025_080534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925013134/form4-05152025_080534.xml","form_type":"4"}},{"id":1147095,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-15T20:17:38.000Z","date":"2025-05-13","kind":"purchase","planned":false,"acquired":true,"shares":1120,"price":3.1637,"value":3543.344,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.045 to $3.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":49323,"source":{"system":"sec-edgar","filing":"0001415889-25-013134","document":"form4-05152025_080534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925013134/form4-05152025_080534.xml","form_type":"4"}},{"id":1150540,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-13T20:13:04.000Z","date":"2025-05-12","kind":"purchase","planned":false,"acquired":true,"shares":12601,"price":3.0395,"value":38300.7395,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.825 to $3.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":48203,"source":{"system":"sec-edgar","filing":"0001415889-25-012770","document":"form4-05132025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925012770/form4-05132025_080500.xml","form_type":"4"}},{"id":1150539,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-13T20:13:04.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":2226,"price":3.6177,"value":8053.0002,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":35602,"source":{"system":"sec-edgar","filing":"0001415889-25-012770","document":"form4-05132025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925012770/form4-05132025_080500.xml","form_type":"4"}},{"id":1150538,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-13T20:13:04.000Z","date":"2025-05-09","kind":"purchase","planned":false,"acquired":true,"shares":33376,"price":3.1928,"value":106562.8928,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $3.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":33376,"source":{"system":"sec-edgar","filing":"0001415889-25-012770","document":"form4-05132025_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588925012770/form4-05132025_080500.xml","form_type":"4"}},{"id":1188946,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:36:48.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":1135,"price":22.4851,"value":25520.5885,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.37 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3013569,"source":{"system":"sec-edgar","filing":"0001415889-25-009198","document":"form4-03282025_090345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925009198/form4-03282025_090345.xml","form_type":"4"}},{"id":1219960,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-03-06T22:32:07.000Z","date":"2025-03-04","kind":"purchase","planned":false,"acquired":true,"shares":4005,"price":21.0245,"value":84203.1225,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.545 to $21.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3012434,"source":{"system":"sec-edgar","filing":"0001415889-25-007263","document":"form4-03062025_100302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588925007263/form4-03062025_100302.xml","form_type":"4"}},{"id":1405184,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:11:37.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":28297265,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2353769},"source":{"system":"sec-edgar","filing":"0000950170-24-107536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107536/ownership.xml","form_type":"4"}},{"id":1405183,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:11:37.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":18922852,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1574005},"source":{"system":"sec-edgar","filing":"0000950170-24-107536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107536/ownership.xml","form_type":"4"}},{"id":1405182,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:11:37.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":4552774,"source":{"system":"sec-edgar","filing":"0000950170-24-107536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107536/ownership.xml","form_type":"4"}},{"id":1405181,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:11:37.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":3927774,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by Frazier Life Sciences X, L.P. (\"FLS X\"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":3927774,"source":{"system":"sec-edgar","filing":"0000950170-24-107536","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107536/ownership.xml","form_type":"4"}},{"id":1501670,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T23:47:57.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":10.3,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064842","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000095017024064842/ownership.xml","form_type":"4"}},{"id":1501669,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T23:47:57.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":32096,"source":{"system":"sec-edgar","filing":"0000950170-24-064842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000095017024064842/ownership.xml","form_type":"4"}},{"id":1508693,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508692,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508691,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508690,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508689,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508688,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508687,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from Footnote 6) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1508686,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T00:10:44.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":2829347,"ownership":{"direct":false,"nature":"By Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000097","document":"wk-form4_1716250233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000097/wk-form4_1716250233.xml","form_type":"4"}},{"id":1533642,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-29T20:32:08.000Z","date":"2024-04-25","kind":"other","planned":false,"acquired":false,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The warrant had no expiration date and was exercisable immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrant had no expiration date and was exercisable immediately."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001415889-24-011664","document":"form4-04292024_080401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588924011664/form4-04292024_080401.xml","form_type":"4"}},{"id":1533641,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-29T20:32:08.000Z","date":"2024-04-25","kind":"sale","planned":false,"acquired":false,"shares":19,"price":64.57,"value":1226.83,"ownership":{"direct":false,"nature":"By: Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2024, Frazier Life Sciences VIII, L.P. exercised a warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share. Frazier Life Sciences VIII, L.P. paid the exercise price on a cashless basis, resulting in the Issuer withholding 19 shares of Common Stock to pay the exercise price and issuing Frazier Life Sciences VIII, L.P. the remaining 1,199,981 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any."}],"balance_after":2829347,"source":{"system":"sec-edgar","filing":"0001415889-24-011664","document":"form4-04292024_080401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588924011664/form4-04292024_080401.xml","form_type":"4"}},{"id":1533640,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-29T20:32:08.000Z","date":"2024-04-25","kind":"other","planned":false,"acquired":true,"shares":1200000,"price":0.001,"value":1200.0,"ownership":{"direct":false,"nature":"By: Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any."}],"balance_after":2829366,"source":{"system":"sec-edgar","filing":"0001415889-24-011664","document":"form4-04292024_080401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588924011664/form4-04292024_080401.xml","form_type":"4"}},{"id":1545339,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:22:13.000Z","date":"2024-04-04","kind":"purchase","planned":false,"acquired":true,"shares":8850,"price":14.5,"value":128325.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences X, L.P.  FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8544187,"source":{"system":"sec-edgar","filing":"0001415889-24-010490","document":"form4-04082024_080405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000141588924010490/form4-04082024_080405.xml","form_type":"4"}},{"id":1558625,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-03-28T20:30:34.000Z","date":"2024-03-26","kind":"purchase","planned":false,"acquired":true,"shares":8429,"price":21.5,"value":181223.5,"ownership":{"direct":false,"nature":"By Frazier Life Sciences X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Frazier Life Sciences X, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C.  The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3008429,"source":{"system":"sec-edgar","filing":"0001415889-24-009330","document":"form4-03282024_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000141588924009330/form4-03282024_080315.xml","form_type":"4"}},{"id":1687216,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-05T00:03:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":17500,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000011","document":"wk-form4_1704413025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619924000011/wk-form4_1704413025.xml","form_type":"4"}},{"id":1712222,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-12-13T22:30:53.000Z","date":"2023-12-11","kind":"other","planned":false,"acquired":false,"shares":145251,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":12.74,"exercise_date":"2019-01-18","expiration_date":"2024-01-18","underlying":"Common Stock","underlying_shares":145251},"source":{"system":"sec-edgar","filing":"0001209191-23-058530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123058530/doc4.xml","form_type":"4"}},{"id":1712221,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-13T22:30:53.000Z","date":"2023-12-11","kind":"other","planned":false,"acquired":true,"shares":145251,"price":12.74,"value":1850497.74,"ownership":{"direct":false,"nature":"By: Frazier Life Sciences VIII, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of Common Stock are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper is one of two managing members of FHM LLC. Dr. Topper disclaims beneficial ownership of the securities held by FLS LP except for his pecuniary interest therein, if any."}],"balance_after":1629366,"source":{"system":"sec-edgar","filing":"0001209191-23-058530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123058530/doc4.xml","form_type":"4"}},{"id":1754655,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-26T20:09:29.000Z","date":"2023-10-24","kind":"purchase","planned":false,"acquired":true,"shares":80000,"price":2.5,"value":200000.0,"ownership":{"direct":true},"balance_after":8764232,"source":{"system":"sec-edgar","filing":"0001209191-23-053662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123053662/doc4.xml","form_type":"4"}},{"id":1874439,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-30T23:03:35.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.72,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033025","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123033025/doc4.xml","form_type":"4"}},{"id":1874438,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T23:03:35.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":21596,"source":{"system":"sec-edgar","filing":"0001209191-23-033025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123033025/doc4.xml","form_type":"4"}},{"id":2057321,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-01-11T00:13:31.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":3900,"derivative":{"underlying":"Common Stock","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001209191-23-002887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123002887/doc4.xml","form_type":"4"}},{"id":2057320,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T00:13:31.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":10600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":10600,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":10600},"source":{"system":"sec-edgar","filing":"0001209191-23-002887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919123002887/doc4.xml","form_type":"4"}},{"id":2061951,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-06T00:00:01.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-23-000020","document":"wf-form4_167296318497904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619923000020/wf-form4_167296318497904.xml","form_type":"4"}},{"id":2151155,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2022-09-26T20:09:37.000Z","date":"2022-09-22","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to one-third of the shares of common stock on September 22, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following two years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":10.02,"expiration_date":"2032-09-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-051239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122051239/doc4.xml","form_type":"4"}},{"id":2190582,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T20:34:26.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":250000,"price":20,"value":5000000.0,"ownership":{"direct":true},"balance_after":8684232,"source":{"system":"sec-edgar","filing":"0001209191-22-045014","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122045014/doc4.xml","form_type":"4"}},{"id":2283867,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Notes","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":37212795.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":2736234},"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2283866,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"purchase","acquired":true,"shares":1764706,"price":17,"value":30000002.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8535337,"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2283865,"issuer":{"id":75097,"kind":"organization","name":"HilleVax, Inc.","symbol":"HLVX"},"owners":[{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":1,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":2,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":3,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T20:23:43.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":2736234,"price":13.6,"value":37212782.4,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are held directly by Frazer Life Sciences X, L.P. (\"FLS X\"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":6770631,"source":{"system":"sec-edgar","filing":"0000899243-22-016310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924322016310/doc4.xml","form_type":"4"}},{"id":2394081,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":4,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":5,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-15T22:00:58.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":112665,"price":7.1006,"value":799989.099,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1484115,"source":{"system":"sec-edgar","filing":"0001209191-22-009821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122009821/doc4.xml","form_type":"4"}},{"id":2397411,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-14T21:51:50.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":9200,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001209191-22-009352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919122009352/doc4.xml","form_type":"4"}},{"id":2447892,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-01-04T22:28:06.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 3, 2022 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":10000,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-22-000010","document":"wf-form4_164133525930529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619922000010/wf-form4_164133525930529.xml","form_type":"4"}},{"id":2562906,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately.  Notwithstanding the foregoing, the Reporting Person shall not be entitled to exercise the Pre-Funded Warrant if it would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Reporting Person, its affiliates and any persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed 9.99% (the \"Maximum Percentage\") of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise, or (ii) the combined voting power of the securities of the Issuer beneficially owned by the Reporting Person and its affiliates and any other persons who are members of a Section 13(d) group with the Reporting Person or its affiliates to exceed the Maximum Percentage of the combined voting power of all of the securities of the Issuer then outstanding following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Maximum Percentage can be changed by the holder upon 61 days notice to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1200000,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2562905,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-21T17:54:32.000Z","date":"2021-09-17","kind":"disposition_to_issuer","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Life Sciences VIII, L.P. entered into an Exchange Agreement with the Issuer pursuant to which, Frazier Life Sciences VIII, L.P. exchanged, on a 1:1 basis, 1,200,000 shares of the Issuer's Common Stock for a prefunded warrant to purchase 1,200,000 shares of the Issuer's Common Stock at an exercise price of  $0.001 per share (the \"Pre-Funded Warrant\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James N. Topper and Patrick J. Heron are the sole managing members of FHM LLC. Mr. Topper, Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1371450,"source":{"system":"sec-edgar","filing":"0001209191-21-057010","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121057010/doc4.xml","form_type":"4"}},{"id":2715984,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata in-kind stock distribution by FHM Life Sciences VIII, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715983,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":true,"shares":96574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By FHM Life Sciences VIII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects shares of Common Stock received from FLS VIII in the in-kind stock distribution described herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares held of record by FHM Life Sciences VIII, L.P. The general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C.  Dr. Topper and Dr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.P. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":96574,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2715982,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":2,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":5,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T21:37:34.000Z","date":"2021-05-10","kind":"other","acquired":false,"shares":2108558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata in-kind stock distribution by Frazier Life Sciences VIII, L.P. (\"FLS VIII\") to its limited partners and general partner for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents shares held of record by FLS VIII. The general partner of FLS VIII is FHM Life Sciences VIII, L.P., and the general partner of FHM Life Sciences VIII, L.P. is FHM Life Sciences VIII, L.L.C. James Topper and Patrick Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FLS VIII. Dr. Topper and Dr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":8434232,"source":{"system":"sec-edgar","filing":"0001209191-21-032151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121032151/doc4.xml","form_type":"4"}},{"id":2862673,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-13T02:36:15.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":11000,"derivative":{"exercise_price":29.7,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-010526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919121010526/doc4.xml","form_type":"4"}},{"id":2919481,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-06T00:04:56.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 4, 2021 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-21-000020","document":"wf-form4_160989148086693.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000162619921000020/wf-form4_160989148086693.xml","form_type":"4"}},{"id":2948245,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":333333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of the Issuer. By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each such person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Life Sciences X, L.P. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":333333,"derivative":{"exercise_price":11.5,"underlying":"Class A Ordinary Shares","underlying_shares":333333},"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948244,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":167000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants will become exercisable on the later of (a) 30 days after the completion of the Issuer's initial business combination or (b) 12 months from the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the \"Board\") of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each of such entity or person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":167000,"derivative":{"exercise_price":11.5,"underlying":"Class A Ordinary Shares","underlying_shares":167000},"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948243,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"purchase","acquired":true,"shares":1000000,"price":10,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Frazier Life Sciences X, L.P. is the record holder of the securities. The reported Class A ordinary shares and warrants are within the 1,000,000 units of the Issuer, as described in the Registration Statement, purchased by Frazier Lifesciences X, L.P. in the Issuer's initial public offering for $10.00 per unit. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of the Issuer. By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each such person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Life Sciences X, L.P. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2948242,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}},{"id":144564,"kind":"person","name":"Frazier Lifesciences Sponsor LLC","position":2,"cik":"0001828906","reported_name":"Frazier Lifesciences Sponsor LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74839,"kind":"organization","name":"Frazier Life Sciences X, L.P.","position":3,"cik":"0001790879","reported_name":"Frazier Life Sciences X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74837,"kind":"organization","name":"FHMLS X, L.P.","position":4,"cik":"0001790880","reported_name":"FHMLS X, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":74838,"kind":"organization","name":"FHMLS X, L.L.C.","position":5,"cik":"0001790811","reported_name":"FHMLS X, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":6,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2020-12-11T21:05:35.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":501000,"price":10,"value":5010000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Frazier Lifesciences Sponsor LLC (the \"Sponsor\") is the record holder of the securities. The reported Class A ordinary shares and warrants are within the [465,000] private placement units of the Issuer, as described in the Issuer's Registration Statement on Form S-1 (File No. 333-250858) (the \"Registration Statement\") under the heading \"Description of Securities,\" purchased by the Sponsor for $10.00 per private placement unit. The private placement units were purchased in a private placement that closed simultaneously with the closing of the Issuer's initial public offering. Each unit consists of one share of Class A ordinary share and one-third of one warrant, with each whole warrant entitling the holder to purchase one share of Class A ordinary share at $11.50 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Frazier Life Sciences X, L.P. is the sole member of Frazier Lifesciences Sponsor LLC. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. Mr. Topper is the Chief Executive Officer and Chairman of the Board of Directors (the \"Board\") of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"By virtue of Mr. Topper's representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Mr. Topper and Mr. Heron may be deemed directors by deputization of the Issuer. As such, each of such entity or person may be deemed to have or share beneficial ownership of the common stock held directly by Frazier Lifesciences Sponsor LLC. Each such entity or person disclaims any such beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":501000,"source":{"system":"sec-edgar","filing":"0001104659-20-134761","document":"tm2037955-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000110465920134761/tm2037955-9_4seq1.xml","form_type":"4"}},{"id":2974670,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T22:15:48.000Z","date":"2020-11-16","kind":"other","acquired":true,"shares":26354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Shares acquired by Dr. Topper through a distribution in-kind from Frazier Healthcare VII, L.P."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Dr. Topper also holds stock options to purchase up to an aggregate of 38,000 shares of the Issuer's Common Stock, which stock options vest according to their terms, in addition to the 80,812 shares of Common Stock that are held directly by Dr. Topper."}],"balance_after":80812,"source":{"system":"sec-edgar","filing":"0001209191-20-059179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120059179/doc4.xml","form_type":"4"}},{"id":2974669,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T22:15:48.000Z","date":"2020-11-16","kind":"other","acquired":true,"shares":22604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Shares acquired by Dr. Topper through a distribution in-kind from Frazier Healthcare V, L.P."}],"balance_after":54458,"source":{"system":"sec-edgar","filing":"0001209191-20-059179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120059179/doc4.xml","form_type":"4"}},{"id":2974668,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T22:15:48.000Z","date":"2020-11-16","kind":"other","acquired":false,"shares":98275,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Frazier Healthcare VII-A, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro rata distribution in-kind by Frazier Healthcare VII-A, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reportable securities are held directly by Frazier Healthcare VII-A, L.P.  FHM VII, L.P. is the general partner of Frazier Healthcare VII-A, L.P.  FHM VII, L.L.C. is the general partner of FHM VII, L.P.  James Topper is one of six managing members of FHM VII, L.L.C.  Dr. Topper disclaims beneficial ownership of the securities held by Frazier Healthcare VII-A, L.P., except to the extent of his pecuniary interest therein, if any."}],"balance_after":199529,"source":{"system":"sec-edgar","filing":"0001209191-20-059179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120059179/doc4.xml","form_type":"4"}},{"id":2974667,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T22:15:48.000Z","date":"2020-11-16","kind":"other","acquired":false,"shares":344860,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Frazier Healthcare VII, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a pro rata distribution in-kind by Frazier Healthcare VII, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reportable securities are held directly by Frazier Healthcare VII, L.P.  FHM VII, L.P. is the general partner of Frazier Healthcare VII, L.P.  FHM VII, L.L.C. is the general partner of FHM VII, L.P.  James Topper is one of six managing members of FHM VII, L.L.C.  Dr. Topper disclaims beneficial ownership of the securities held by Frazier Healthcare VII, L.P., except to the extent of his pecuniary interest therein, if any."}],"balance_after":700171,"source":{"system":"sec-edgar","filing":"0001209191-20-059179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120059179/doc4.xml","form_type":"4"}},{"id":2974666,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-18T22:15:48.000Z","date":"2020-11-16","kind":"other","acquired":false,"shares":973612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Frazier Healthcare V, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution in-kind by Frazier Healthcare V, L.P. to its limited partners for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities were held directly by Frazier Healthcare V, L.P.  FHM V, L.P. is the general partner of Frazier Healthcare V, L.P.  FHM V, L.L.C. is the general partner of FHM V, L.P.  James Topper is one of five managing members of FHM V, L.L.C.  Dr. Topper disclaims beneficial ownership of the securities held by Frazier Healthcare V, L.P., except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-059179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120059179/doc4.xml","form_type":"4"}},{"id":2975200,"issuer":{"id":130904,"kind":"organization","name":"Allena Pharmaceuticals, Inc.","symbol":"ALNA"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-18T16:21:28.000Z","date":"2020-11-17","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of shareholders."}],"balance_after":14000,"derivative":{"exercise_price":1.45,"expiration_date":"2030-11-16","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-20-059087","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1624658/000120919120059087/doc4.xml","form_type":"4"}},{"id":3003145,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214281},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003144,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1390376,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1390376},"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003143,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1917157,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003142,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":214281,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1604657,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3003141,"issuer":{"id":1836,"kind":"organization","name":"Tarsus Pharmaceuticals, Inc.","symbol":"TARS"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-21T00:01:18.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1390376,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. (\"FLS LP\").  The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC.  James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP.  Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein."}],"balance_after":1390376,"source":{"system":"sec-edgar","filing":"0001209191-20-055425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819790/000120919120055425/doc4.xml","form_type":"4"}},{"id":3109260,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T17:42:29.000Z","date":"2020-06-12","kind":"other","acquired":false,"shares":1456854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution in-kind by Frazier Life Sciences IX, L.P. (\"FLS IX\") to its limited partners for no consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents shares held of record by FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":5827415,"source":{"system":"sec-edgar","filing":"0001209191-20-037031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120037031/doc4.xml","form_type":"4"}},{"id":3136741,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2020-05-22T21:05:22.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to James Topper continuing in service on the Board through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":36.85,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-031805","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120031805/doc4.xml","form_type":"4"}},{"id":3186711,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-02T16:32:42.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":4976,"price":2.16,"value":10748.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person, who elected to take unrestricted shares in lieu of cash compensation for services as a director, pursuant to the Issuer's nonemployee director compensation plan. The number of shares issued was determined by dividing the cash compensation otherwise payable with respect to the quarter by the price of a share on the date of the grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences VIII, L.P. (\"FLS-VIII\"). FHM Life Sciences VIII, L.P. (\"FHM-VIII L.P.\") serves as the sole general partner of FLS-VIII and owns no shares directly. FHM Life Sciences VIII, LLC (\"FHM-VIII LLC\") serves as the sole general partner of FHM-VIII L.P. and owns no shares directly. James N. Topper and Patrick Heron are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein."}],"balance_after":3195055,"source":{"system":"sec-edgar","filing":"0001567619-20-007438","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000156761920007438/doc1.xml","form_type":"4"}},{"id":3233208,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":432802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":432802},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233207,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":1049175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049175},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233206,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":2977242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2977242},"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233205,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":550000,"price":18,"value":9900000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":5009219,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233204,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":432802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":4459219,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233203,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":1049175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":4026417,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3233202,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":2,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":3,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T18:59:31.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":2977242,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Patrick J. Heron and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Each of Mr. Heron, Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficial ownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":2977242,"source":{"system":"sec-edgar","filing":"0001209191-20-015666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919120015666/doc4.xml","form_type":"4"}},{"id":3273511,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-02-13T22:09:32.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 12, 2020, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":11000,"derivative":{"exercise_price":16.56,"expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-20-009327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120009327/doc4.xml","form_type":"4"}},{"id":3286296,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":1074467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1074467},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286295,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":2099019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2099019},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286294,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":6360272,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6360272},"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286293,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"purchase","acquired":true,"shares":500000,"price":17,"value":8500000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":10542790,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286292,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":1074467,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":10042790,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286291,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":2099019,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":8968323,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3286290,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":2,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":3,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":4,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-06T15:29:42.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":6360272,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock had no expiration date and automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":6869304,"source":{"system":"sec-edgar","filing":"0001209191-20-007100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120007100/doc4.xml","form_type":"4"}},{"id":3312445,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":108752,"kind":"organization","name":"Frazier Life Sciences VIII, L.P.","position":1,"cik":"0001655827","reported_name":"Frazier Life Sciences VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108753,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.P.","position":3,"cik":"0001698755","reported_name":"FHM LIFE SCIENCES VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108754,"kind":"organization","name":"FHM LIFE SCIENCES VIII, L.L.C.","position":4,"cik":"0001698823","reported_name":"FHM LIFE SCIENCES VIII, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":5,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-13T15:47:04.000Z","date":"2020-01-09","kind":"sale","acquired":false,"shares":50000,"price":5.0002,"value":250010.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held directly by Frazier Life Sciences VIII, L.P. (\"FLS LP\"). FHM Life Sciences VIII, L.P. (\"FHM LP\") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. (\"FHM LLC\") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any."}],"balance_after":1299953,"source":{"system":"sec-edgar","filing":"0001209191-20-003162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000120919120003162/doc4.xml","form_type":"4"}},{"id":3317737,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-01-07T01:00:29.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":7650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2020 and 1/12th of the shares subject to the option shall vest monthly thereafter."}],"balance_after":7650,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0000899243-20-000637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341382/000089924320000637/doc4.xml","form_type":"4"}},{"id":3323315,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":26591,"kind":"person","name":"Topper James N","position":1,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-03T16:26:53.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":5018,"price":2.142,"value":10748.556,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":5018,"derivative":{"exercise_price":3.42,"expiration_date":"2029-12-30","underlying":"Common Stock","underlying_shares":5018},"source":{"system":"sec-edgar","filing":"0001567619-20-000348","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000156761920000348/doc1.xml","form_type":"4"}},{"id":3385431,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":145854,"kind":"organization","name":"Frazier Life Sciences IX, L.P.","position":1,"cik":"0001720320","reported_name":"Frazier Life Sciences IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26591,"kind":"person","name":"Topper James N","position":2,"cik":"0001341382","reported_name":"Topper James N","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":37276,"kind":"person","name":"Heron Patrick J","position":3,"cik":"0001365617","reported_name":"Heron Patrick J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145856,"kind":"organization","name":"FHMLS IX, L.L.C.","position":4,"cik":"0001782791","reported_name":"FHMLS IX, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":145855,"kind":"organization","name":"FHMLS IX, L.P.","position":5,"cik":"0001782789","reported_name":"FHMLS IX, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Notes","published_at":"2019-10-30T17:04:17.000Z","date":"2019-10-29","kind":"exercise","acquired":false,"reported_value":20575342.48,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares reported herein are held of record by Frazier Life Sciences IX, L.P. (\"FLS IX\"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2020-05-07","underlying":"Common Stock","underlying_shares":1353640},"source":{"system":"sec-edgar","filing":"0001209191-19-054525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782789/000120919119054525/doc4.xml","form_type":"4"}}],"next_cursor":"2019-10-30T17:04:17.000000Z,3385431"}